Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pliant Therapeutics Inc
(NQ:
PLRX
)
15.00
-0.19 (-1.25%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pliant Therapeutics Inc
< Previous
1
2
3
Next >
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
November 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
October 17, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
October 01, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 24, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
September 10, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
August 28, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
August 26, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
July 15, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
June 13, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 12, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
June 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
May 21, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
May 14, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
May 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 06, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
May 01, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
April 02, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
March 27, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
March 12, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
February 27, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
February 26, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
February 07, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
February 04, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
November 13, 2023
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.